Amal Therapeutics becomes a subsidiary of a German Pharma giant
Posted on 16.07.2019 in News
16.7.2019 – Since its establishment, Amal Therapeutics has raised more than €40 million in venture capital in addition to grants among others. The biotech startup and spinoff from the University of Geneva is now a subsidiary of the German pharma company, Boehringer Ingelheim, which acquired all shares of the latter for EUR 325 million.
